MedTrace Logo

A CR-UK Phase I Trial of LY3143921

NCT03096054 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2024-12-17

No results posted yet for this study

Summary

This clinical study is looking at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims are to find out the maximum dose of LY3143921 hydrate that can be given safely to patients, more about the potential side effects and how they can be treated

Conditions

  • A. Colorectal Cancer
  • B. High Grade Serous Ovarian Cancer
  • C. Non Small-cell Lung Cancer (squamous Cell Variant)
  • D. Squamous Carcinoma of the Oesophagus
  • E. Squamous Carcinoma of the Head and Neck (HPV Negative)
  • F. Urothelial Cancer
  • G. Breast Cancer (triple Negative Type)
  • H. Pancreatic Cancer

Interventions

DRUG

LY3143921 hydrate

LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096054 on ClinicalTrials.gov